2020
Response criteria for intratumoral immunotherapy in solid tumors: ItRECIST.
Goldmacher G, Khilnani A, Andtbacka R, Luke J, Hodi F, Marabelle A, Harrington K, Perrone A, Tse A, Madoff D, Schwartz L. Response criteria for intratumoral immunotherapy in solid tumors: ItRECIST. Journal Of Clinical Oncology 2020, 38: 3141-3141. DOI: 10.1200/jco.2020.38.15_suppl.3141.Peer-Reviewed Original ResearchLesion responseResponse assessmentIntratumoral immunotherapySolid tumorsTarget lesion responseModification of therapyResponse Evaluation CriteriaRoutine clinical practiceOverall response assessmentUnique treatment strategyInjected lesionsIT drugsRECIST 1.1Immunotherapy trialsNew lesionsTumor burdenMetastatic melanomaTrial protocolClinical trialsInitial progressionTreatment strategiesTherapeutic modalitiesLesion assessmentNadir valuesTreatment evolves
2019
Interventional oncology: aiming globally to be the 4 th pillar of cancer care
Madoff DC, Chapiro J, Pua U. Interventional oncology: aiming globally to be the 4 th pillar of cancer care. Chinese Clinical Oncology 2019, 8: 56. PMID: 31968980, DOI: 10.21037/cco.2019.12.12.Peer-Reviewed Original ResearchConceptsIO therapyInterventional oncologyClinical OncologyNational Comprehensive Cancer NetworkComprehensive Cancer NetworkDisease treatment guidelinesOncologic patient managementOncologic communityPalliative settingTreatment guidelinesOncologic careInterventional oncologistsMedical oncologyCancer careClinical trialsTreatment strategiesPatient managementPatient allocationCancer NetworkInterventional radiologyOncologyTherapyEuropean SocietyRadiation oncologyAmerican Society
2010
Exploratory Study of Hepatic Arterial Infusion Oxaliplatin With Systemic 5-Fluorouracil/Bevacizumab in Patients With Refractory Solid Tumor and Extensive Liver Metastases
Camacho LH, Garcia S, Panchal AM, Lim J, Hong DS, Ng C, Madoff DC, Fu S, Gayed I, Kurzrock R. Exploratory Study of Hepatic Arterial Infusion Oxaliplatin With Systemic 5-Fluorouracil/Bevacizumab in Patients With Refractory Solid Tumor and Extensive Liver Metastases. Clinical Colorectal Cancer 2010, 9: 311-314. PMID: 21208846, PMCID: PMC3088086, DOI: 10.3816/ccc.2010.n.045.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabColorectal NeoplasmsDrug Resistance, NeoplasmFemaleFluorouracilHepatic ArteryHumansInfusions, Intra-ArterialLeucovorinLiver NeoplasmsMaleMiddle AgedOrganoplatinum CompoundsOvarian NeoplasmsOxaliplatinPilot ProjectsSalvage TherapySurvival RateTomography, X-Ray ComputedTreatment OutcomeConceptsExtensive liver metastasesRefractory solid tumorsLiver metastasesTotal bilirubinSolid tumorsBaseline serum total bilirubinHepatic arterial infusion (HAI) oxaliplatinMedian Child-Pugh scoreAdvanced refractory malignanciesGrade 1 fatigueMedian total bilirubinRegional hepatic therapySystemic anticancer agentsChild-Pugh scoreCommon side effectsSerum total bilirubinPilot clinical trialElevated bilirubinLiver involvementPartial responseHepatic insufficiencyMedian ageRefractory malignanciesClinical trialsDisease progression